{
    "clinical_study": {
        "@rank": "61943", 
        "arm_group": [
            {
                "arm_group_label": "Dalantercept plus axitinib", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous (SC) injection of Dalantercept once every 3 weeks and Oral axitinib BID for continuous dosing."
            }, 
            {
                "arm_group_label": "Axitinib plus placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral BID"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of Part 1 of this study is to evaluate the safety and tolerability of\n      dalantercept in combination with axitinib in patients with advanced renal cell carcinoma\n      (RCC) to determine the recommended dose level of dalantercept in combination with axitinib\n      for Part 2.\n\n      The purpose of Part 2 of this study is to determine whether treatment with dalantercept in\n      combination with axitinib prolongs progression free survival (PFS) compared to axitinib\n      alone in patients with advanced renal cell carcinoma (RCC)."
        }, 
        "brief_title": "Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Histologically confirmed, advanced, predominantly clear cell renal cell carcinoma\n             (RCC).\n\n          -  Part 1:  Progression of disease following up to three lines of prior therapy,\n             including at least one approved VEGF receptor tyrosine kinase inhibitor for RCC.\n             Adjuvant therapy is permitted as one line of prior therapy.\n\n          -  Part 2:  Progression of disease following one first-line regimen of a VEGF receptor\n             tyrosine kinase inhibitor (either sunitinib or pazopanib).\n\n          -  A minimum of 2 weeks since the last dose of prior therapy (a minimum of 4 weeks since\n             bevacizumab +/- interferon).\n\n          -  Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors\n             (RECIST) v1.1.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Clinical laboratory values within acceptable ranges within 72 hours prior to study\n             day 1.\n\n        Key Exclusion Criteria:\n\n          -  Clinically significant organ/system disease unrelated to RCC that in the judgment of\n             the investigator should preclude treatment with dalantercept or axitinib.\n\n          -  Clinically significant cardiovascular risk.\n\n          -  Known central nervous system (CNS) metastases or leptomeningeal disease.  Patients\n             with CNS metastases treated with whole brain radiotherapy, gamma knife, and/or\n             surgery who are considered stable by CNS imaging and are not being treated with\n             corticosteroids within 6 weeks prior to study day 1 may be enrolled.\n\n          -  Active gastrointestinal (GI) bleeding, unrelated to RCC.\n\n          -  Any active malignancy, other than RCC, for which chemotherapy or other anti-cancer\n             therapy is indicated.  Patients with adequately treated non-melanoma skin cancer, in\n             situ cancer, or other cancer from which the subject has been disease-free for at\n             least 5 years will be permitted.\n\n          -  Any lesion invading or having encasement \u2265 180 degrees around the wall of a major\n             blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance\n             imaging (MRI).\n\n          -  Radiotherapy within 2 weeks prior to study day 1.\n\n          -  Lack of recovery from toxic effects of previous chemotherapy, radiation therapy,\n             biologic therapy, and/or experimental therapy to \u2264 grade 1 with the exception of\n             alopecia, or if stabilized under adequate medical control.\n\n          -  Patients undergoing renal dialysis.\n\n          -  Major surgery within 4 weeks prior to study day 1 (patients must have recovered\n             completely from any previous surgery prior to study day 1).\n\n          -  Any active infection requiring parenteral antibiotic therapy within 1 month prior to\n             study day 1 or systemic antibiotics within 2 weeks of study day 1.\n\n          -  Anti-coagulation therapy (e.g., clopidogrel, dabigatran, warfarin, and heparin).\n\n          -  Current use of drugs or substances that interact with cytochrome P450 enzymes.\n\n          -  Peripheral edema \u2265 grade 2 within 2 weeks prior to study day 1.\n\n          -  BMI < 16 kg/m2\n\n          -  Clinically significant active pulmonary risk including pulmonary hypertension and\n             pulmonary edema within 12 months of study day 1 or pulmonary embolism within 6 months\n             of study day 1.\n\n          -  Bleeding diathesis including clinically significant platelet disorders or active\n             hemoptysis (defined as bright red blood of \u2265 1/2 teaspoon [2.5 mL] in any 24 hour\n             period) within 6 months prior to study day 1.  For clinically significant epistaxis\n             within 4 weeks prior to study day 1, no risk of further bleeding must be clearly\n             documented.\n\n          -  Any prior treatment with dalantercept or any other agent targeting ALK1 pathway.\n\n          -  Any prior treatment with axitinib.\n\n          -  Pregnant or lactating female patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727336", 
            "org_study_id": "A041-04", 
            "secondary_id": "ACE-041"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dalantercept plus axitinib", 
                "intervention_name": "Dalantercept and axitinib", 
                "intervention_type": "Drug", 
                "other_name": "ACE-041, Inlyta"
            }, 
            {
                "arm_group_label": "Axitinib plus placebo", 
                "intervention_name": "Axitinib and placebo", 
                "intervention_type": "Drug", 
                "other_name": "Inlyta"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma", 
        "overall_contact": {
            "email": "clinicaltrials041@acceleronpharma.com", 
            "last_name": "Clinical Trials Manager"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part 1: Number of participants with Adverse Events as a measure of safety and tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed from time of first dose to approximately 30 days after last dose (approximately 6 months)."
            }, 
            {
                "measure": "Part 2: Progression free survival (PFS).", 
                "safety_issue": "No", 
                "time_frame": "Progression free survival is defined as the time from the date of the randomization to the first documented disease progression (according to RECIST v1.1) or death due to any cause (approximately 6 months)."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part 2: Overall survival.", 
                "safety_issue": "No", 
                "time_frame": "Patients to be contacted every 3 months for up to 12 months (anticipated) for survival follow-up, as well as tumor assessment scans if progression of disease has not previously been documented."
            }, 
            {
                "measure": "Part 2: Time to tumor progression.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 30 days after last dose of study drug, or up to approximately 6 months from initiation of treatment."
            }, 
            {
                "measure": "Part 2: Objective response rate.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 30 days after last dose of study drug, or up to approximately 6 months from initiation of treatment."
            }, 
            {
                "measure": "Part 2: Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 30 days after last dose of study drug, or up to approximately 6 months from initiation of treatment."
            }, 
            {
                "measure": "Part 2: Disease control rate.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 30 days after last dose of study drug, or up to approximately 6 months from initiation of treatment for evaluable patients who meet the criteria for CR, PR or SD a minimum of 6 weeks after initiation of dosing."
            }, 
            {
                "measure": "Part 2: PD biomarker activities.", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 30 days after the last dose of dalantercept \u00b1 10 days."
            }
        ], 
        "source": "Acceleron Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acceleron Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}